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Abstract 
 
Background and aims: The cost effectiveness of cascade testing for familial hypercholesterolaemia 
(FH) is well recognised. Less clear is the cost effectiveness of FH screening when it includes case 
identification strategies that incorporate routinely available data from primary and secondary care 
electronic health records.  
Methods: Nine strategies were compared, all using cascade testing in combination with different 
index case approaches (primary care identification, secondary care identification, and clinical 
assessment using the Simon Broome (SB) or Dutch Lipid Clinic Network (DLCN) criteria). A 
decision analytic model was informed by three systematic literature reviews and expert advice 
provided by a NICE Guideline Committee.  
Results: The model found that the addition of primary care case identification by database search for 
patients with recorded total cholesterol >9.3 mmol/L was more cost effective than cascade testing 
alone. The incremental cost-effectiveness ratio (ICER) of clinical assessment using the DLCN criteria 
was £3,254 per quality-adjusted life year (QALY) compared with case-finding with no genetic testing. 
The ICER of clinical assessment using the SB criteria was £13,365 per QALY (compared with 
primary care identification using the DLCN criteria), indicating that the SB criteria was preferred 
because it achieved additional health benefits at an acceptable cost. Secondary care identification with 
either the SB or DLCN criteria, was not cost effective, alone (dominated and dominated respectively) 
or combined with primary care identification (£63, 514 per QALY, and £82,388 per QALY 
respectively).  
Conclusions: Searching primary care databases for people at high risk of FH followed by cascade 
testing is likely to be cost-effective. 
 
Key words: Familial-Hypercholesterolaemia/Markov model/Cost effectiveness/Cascade 
testing/General Practice/secondary Care Registers 
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Introduction 
 
Familial hypercholesterolaemia (FH) is characterised by an inherited genetic mutation which causes a 
high cholesterol concentration from birth. People with FH have a higher risk of coronary heart disease 
(CHD), particularly at younger ages.1 Once diagnosed, lifestyle changes and lipid modification 
treatment substantially reduce the risk of CHD.2,3  
 
It is estimated that between 115,000 and 267,000 people in England and Wales have FH but only 
18,000 are currently diagnosed, representing an opportunity to substantially reduce the mortality and 
morbidity associated with the disease.1,4,5 Cascade testing is recommended by clinical guidelines to 
identify people with FH who are currently undiagnosed because it has been shown to be effective and 
cost effective.6-9 Cascade testing is the process of inviting relatives of people currently diagnosed with 
FH to undergo genetic testing to see if they carry the family mutation. However, it has been estimated 
that only half of all carriers are likely to be identified using this strategy.5  
 
New evidence has emerged on the effectiveness of searching primary care and secondary care 
databases for people at high risk of FH based on routinely collected information on biochemical tests, 
clinical signs including xanthomas, personal history of cardiovascular disease (CVD) and family 
medical history.10-16 Examples of biological markers are high LDL-cholesterol (LDL-C) and high total 
cholesterol. Other characteristics may include a family history of early CHD. Based on these 
characteristics, the clinician may assess the patient against standard FH diagnostic criteria, usually the 
Simon Broome (SB) or Dutch Lipid Clinic Network (DLCN) criteria. Those identified with possible 
FH would be referred to a lipid clinic for specialist consultation and genetic testing.  
 
The cost effectiveness of searching databases should be established prior to wider adoption because of 
the resource impact on healthcare providers and the National Health Service (NHS). Activities that 
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require resource reallocation include informatics setup, training staff in GP surgeries, contacting 
patients to invite them for further assessment, lipid clinic consultations, genetic testing and treatment 
following a positive diagnosis. Whether this resource impact is cost effective is influenced by the 
likelihood people identified for further assessment actually have FH, the diagnostic accuracy of the 
diagnostic criteria, the take up rates of clinical assessment and cascade testing, and the costs and 
health benefits associated with long term lipid modification treatment. 
 
Recommendations in the original NICE guideline were based on economic modelling of cascade 
testing only conducted by Nherera et al. in 2011.6 The 2017 update identified studies supporting the 
cost effectiveness of cascade testing but revealed that the cost effectiveness of new index case 
identification in primary care or secondary care had not been investigated.6-9,17 The present economic 
analysis was developed to provide this evidence. 
 
 
Methods 
 
Population and subgroups 
 
There are six groups of people that have the potential to come in to contact with the interventions: 
current index cases, potential new index cases from primary or secondary care, and the relatives of 
people in each of these three groups.  
 
Current and potential new index cases, consisting of the groups of people with a current clinical 
diagnosis, people identified in a primary care database as requiring further investigation, and people 
identified in a secondary care database as requiring further investigation, were further stratified to 
differentiate people that had a monogenic cause of their hypercholesterolaemia (autosomal dominant 
FH caused by mutations in the LDLR, APOB and PCSK9 genes) and those with multifactorial 
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hypercholesterolaemia. Within the multifactorial group will be individuals with a polygenic aetiology 
due to co-inheritance of common LDL-C-raising variants (“polygenic hypercholesterolaemia”).18,19 
Genetically confirmed monogenic FH is associated with a greater risk of CHD compared with 
polygenic hypercholesterolaemia.20,21 For the purposes of modelling, a simplifying assumption was 
made that relatives cannot carry both monogenic FH and polygenic hypercholesterolaemia. Long term 
modelling was conducted including cohorts of males and females beginning between age 40 and 70 
that were broadly representative of the UK population within these age bands.  
 
Strategies compared 
 
The strategies that were compared in the analysis are summarised in Table 1. The diagnostic pathway 
and resource use associated with each strategy was mapped in consultation with the NICE Guideline 
Committee.17 The full description of each strategy along with diagrams in the form of a decision tree 
are provided in the Supplementary Material.  
 
Table 1: Characteristics of strategies compared in the analysis 
Strategy Genetic 
cascade testing 
Search 
primary 
care 
database 
Search 
secondary care 
database 
SB criteria for 
clinical 
assessment 
(base case 
possible & 
definite) 
DLCN criteria 
for clinical 
assessment 
(base case 
score > 5) 
Strategy 1      
Strategy 2      
Strategy 3      
Strategy 4      
Strategy 5      
  7 
Strategy 6      
Strategy 7      
Strategy 8      
Strategy 9 a     
SB: Simon Broome; DLCN: Dutch Lipid Clinic Network 
a Cascade testing offered to the relatives of currently diagnosed index cases only. 
 
The NICE guideline committee selected the SB and DLCN criteria as the most widely used clinical 
assessment tools out of nine available.22 Onward referral for genetic testing is typically considered 
when a patient has ‘possible’ or ‘definite’ FH on the SB criteria or a score greater than 5 on the 
DLCN criteria.1 Genetic testing is the gold standard for diagnosing monogenic FH.  
 
Modelling approach 
 
The setting of interest is the NHS in England and Wales. Costs were derived using the perspective of 
the NHS and include direct medical costs, such as the staff cost of searching databases, conducting 
clinical assessment in primary or secondary care settings and genetic testing. The perspectives of 
people with FH and multifactorial hypercholesterolaemia were adopted for health benefits. A lifetime 
time horizon was adopted. Both costs and health outcomes were discounted at an annual rate of 3.5% 
as specified by NICE. 
 
The structure of the model consisted of five modules. The first was a decision tree capturing short 
term identification, diagnosis and cost outcomes. Short term outcomes included the proportion of 
people with FH who were treated vs. untreated and the cost of searching electronic health records, 
clinical assessment and genetic testing. The four remaining modules were Markov traces that captured 
long term consequences. People were assigned to the ‘Untreated FH’ module if they were incorrectly 
diagnosed as not having FH (false negatives) or because they were not identified, as there was no 
opportunity to within that strategy. This module was adapted from the cost-effectiveness analysis of 
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statin treatment for the primary and secondary prevention of cardiovascular disease in NICE CG181. 
This model had eight alive health states plus seven transition states and was adjusted to account for 
the different risk profile of people with FH. People were assigned to the ‘Treated FH’ module if they 
were correctly identified and diagnosed with FH. Costs and treatment effect were based on 
atorvastatin 80mg. People with polygenic hypercholesterolaemia were assigned to the ‘Untreated 
polygenic’ module if they did not come in to contact with a health care professional as part of the 
intervention and health outcomes were identical to the CG181 model. If people with polygenic 
hypercholesterolaemia were already on statins prior to intervention or came in to contact with health 
care they were assigned to the ‘Treated polygenic’ module. A simplifying assumption was made that 
all people in this module were treated with atorvastatin 20mg although it is recognised that, in 
practice, people with polygenic hypercholesterolaemia will be prescribed this treatment only if their 
QRISK is >10%. Costs were updated to the most recent financial year for which reference costs were 
available, 2015-16. Probabilistic sensitivity analysis (PSA) was conducted to enable an assessment of 
the joint uncertainty in the results and to calculate the probability that each intervention was cost 
effective.  
 
Outcomes 
 
The short term module reported the number and proportion of people with FH and polygenic 
hypercholesterolaemia who were treated vs. untreated. It also calculated short term diagnostic 
outcomes of interest, such as the number of genetic tests conducted as a result of false positive clinical 
assessments and the total short term economic cost by subpopulation. Long term costs and quality-
adjusted life years (QALYs) were then included in the overall assessment of cost-effectiveness. The 
main outcome of interest was the incremental cost-effectiveness ratio (ICER). This was the difference 
in costs divided by the difference in health benefits achieved by a strategy compared with the next 
best alternative.  
 
  9 
 
Input parameters 
 
The key input parameters are provided in the Supplementary Material and briefly summarised below. 
 
The number of people with a current clinical diagnosis of FH was informed by an audit of lipid clinics 
in the UK in 2010.5 The proportion of people with a current clinical diagnosis that actually had a 
functional mutation in the LDLR, APOB or PCSK9 gene was taken from the experience of the Welsh, 
Scottish and Wessex FH services.9 A conservative estimate of 1/500 was used for the prevalence of 
FH in the general population.1 This was varied up to 1/217 in sensitivity analysis.4 The size of the 
adult population of England and Wales was used to represent the number of people registered in 
primary care databases and sourced from the Office of National Statistics.  
 
The availability of relevant cholesterol data was estimated at 31% in the UK context.10,23 This value 
affects the overall resource impact but not the cost-effectiveness of primary care case finding as there 
are few fixed costs within the model. The take up of clinical assessment by people identified by a 
primary care database search was informed by the general practice and workplace identification 
cohorts of an Australian study.14  The prevalence of FH in people with early myocardial infarction 
(MI) was informed by a UK study of people genetically tested for LDLR gene deletions or 
duplications.24 In sensitivity analysis, this was varied between the lower 95% confidence interval from 
the same study up to an alternative mean estimate from a study based on clinical assessment to 
diagnose FH in the secondary care setting.24,25 The take up of clinical assessment and genetic testing 
by people with early MI was informed by the UK study of genetically-confirmed prevalence and 
varied by +/-25% in sensitivity analysis.24 The prevalence of people with early MI was sourced from a 
summary of the epidemiology of cardiovascular disease in the UK.26 The number of relatives invited 
for cascade testing per index case was estimated from a finding that 1.33 relatives were genetically 
tested per index case in the Scottish, Welsh and Wessex FH services and that 59.89% relatives take up 
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cascade testing (1.33/0.5989 = 2.22).9,27 This parameter was varied in sensitivity analysis between 1 
relative, based on a worst-case scenario, and 12 relatives, based on an optimistic assumption used in a 
previous NICE costing report from 2009. The accuracy of the SB and DLCN diagnostic criteria was 
established through systematic review and meta-analysis.  
 
In the base case a more inclusive ‘rule out’ profile was used for referral to a lipid clinic and genetic 
testing: possible or definite according to the SB criteria and a score >5 for the DLCN criteria because 
sensitivity was prioritised over specificity by the NICE guideline committee because correctly 
diagnosing people with FH was valued over the inconvenience of additional assessment due to false 
positive results. Sensitivity analysis using the ‘definite’ only criteria for each tool was also examined.  
 
The increased risk of CHD due to FH was based on data from the Simon Broome register (personal 
communication, S. Humphries).3  The relative treatment effect of lipid modification on CVD risk was 
assumed to be the same in the FH population as in the general population due to a lack of evidence on 
the adult FH population identified in the systematic review conducted for the 2017 update to the 
NICE guideline. Placebo-controlled trials of lipid modification have not included people with FH 
because it is unethical to withhold treatment from patients with severe hypercholesterolaemia due to 
high lifetime risk of CHD. Appropriate treatment with statins was assumed to result in the same 
relative reduction in CVD event risk whether that was achieved with statins or ezetimibe or a 
combination of both in the base case. A recent study of a Spanish cohort suggested that the base case 
risks of CHD events may have been too high (15% to 44% in our model vs. 7.5% in SAFEHEART).28 
A sensitivity analysis was conducted in which the model outputs for patients with treated FH were 
calibrated to match the outcomes observed in this trial.  
 
Costs 
 
The cost of genetic testing was obtained from the UK Genetic Testing Network. Several laboratories 
offer FH testing services throughout England and Wales and the median cost was used in the base 
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case. The highest and lowest costs were used in sensitivity analysis. Staff costs were obtained from 
the Personal Social Services Research Unit’s report of unit costs in the NHS.29 Itemised resource use 
used to calculate healthcare and admin staff inputs associated with genetic testing were obtained from 
a recent cost-utility analysis of genetic cascade screening.9 The unit cost of lipid modification for 
people diagnosed with FH was obtained from the NHS Drug Tariff. The proportion of people 
prescribed atorvastatin 80mg, rosuvastatin 40mg and Ezetimibe 10mg was 71%, 15.5% and 40% 
respectively. These proportions do not sum to 100% because people with FH are prescribed one or a 
combination of medicines. The proportions were obtained from an audit of FH services in the UK.5 
Detailed cost inputs are provided in supplementary material.  
 
Results 
 
Short term results 
 
Under the base case settings of the model, the maximum number of people with FH that were able to 
be diagnosed (at 100% take up, sensitivity and specificity) was 43,961 (  
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Figure 1). This assumed a data availability rate of 31% in primary care, which crucially determined 
the number of people that are able to be found by the case finding strategies. This figure was also 
based on the number of relatives approached for cascade testing, set at 2 in the base case. 
 
Strategy 2, cascade testing only, resulted in 2,354 relatives being diagnosed and treated, increasing the 
proportion of people with FH in the model who were treated from 19% to 25%. Strategy 3 and 
Strategy 4, primary care case identification with the SB and DLCN criteria respectively, had very 
similar results with approximately 6,100 new FH index case diagnoses in addition to over 2,000 new 
diagnoses resulting from cascade testing the relatives of the new index cases. This increases to 37% 
the people with FH in the model being identified. Due to the relatively small numbers of people with 
early MI, secondary care case identification strategies identified close to 600 relatives of new index 
cases with FH. The strategy that diagnosed the most number of people with FH was Strategy 7, 
primary and secondary care case identification with clinical assessment using the SB criteria.  
 
Total short term economic cost was calculated for each strategy by setting (Table 2). These figures 
take account of the opportunity cost of a consultation taken up for clinical diagnosis, rather than 
additional resource on staff costs in general practice.  This analysis found that most of the short term 
cost of the strategies is borne by secondary care and genetic testing services. Apart from Strategy 1 
(no intervention), the lowest short term economic cost was £11 million for Strategy 2 (cascade testing 
only) and the highest was £58 million for Strategy 7, case identification in both primary and 
secondary care. Table 2 also shows the number of unnecessary genetic tests, which are those that find 
a person does not actually have FH following a false positive clinical assessment. The highest number 
of unnecessary genetic tests occur in Strategy 7 and relatively few occur in Strategy 3 and Strategy 4. 
In line with the specificity of each diagnostic criteria, there were more unnecessary genetic tests using 
the combined possible and definite SB criteria compared with the DLCN criteria using a score >5. 
The number of other, appropriate genetic tests is made up of true positive clinical assessments and 
relatives tested through cascade testing. Strategies that involve primary care database searching (3, 4, 
7, 8) achieve similarly high numbers of appropriate genetic testing. These short term results highlight 
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the trade-off between the diagnostic accuracy of the clinical assessment tools, the cost of, and setting 
in which, the strategies are implemented, and the need to consider long term results to determine the 
most cost-effective strategy.  
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Figure 1: Base case short term outcomes, proportion of treated vs. untreated 
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Table 2: Total short term economic cost, base case 
Strategy Primary 
care 
Secondary 
care 
Genetic 
testing 
Total short 
term cost 
Number of 
unnecessary 
genetic tests 
Cost of 
unnecessary 
genetic tests 
Number of 
other 
genetic 
tests 
Cost of other 
genetic tests 
False 
negatives 
missed by 
clinical 
assessment 
1. No cascade testing and no case 
identification 
- - - £0 0 £0 0 £0 0 
2. Cascade testing £0 £4,919,686 £6,220,205 £11,139,892 0 £0 19,763 £6,220,205 0 
3. Primary care case identification, 
clinical assessment with SB criteria 
£2,446,705 £8,975,760 £10,793,647 £22,216,112 7,226 £2,709,936 27,935 £8,083,711 1,666 
4. Primary care case identification, 
clinical assessment with DLCN 
criteria 
£2,607,297 £8,586,321 £10,086,798 £21,280,417 5,503 £2,063,808 27,669 £8,022,990 2,105 
5. Secondary care case identification, 
clinical assessment with SB criteria 
£0 £20,498,803 £26,744,760 £47,243,563 53,486 £20,057,415 21,812 £6,687,345 150 
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6. Secondary care case identification, 
clinical assessment with DLCN 
criteria 
£0 £20,429,396 £21,947,266 £42,376,662 40,734 £15,275,142 21,745 £6,672,124 189 
7. Primary and secondary care case 
identification, clinical assessment 
with SB criteria 
£2,446,705 £24,554,877 £31,318,202 £58,319,784 60,713 £22,767,351 29,984 £8,550,851 1,816 
8. Primary and secondary care case 
identification, clinical assessment 
with DLCN criteria 
£2,607,297 £24,096,031 £25,813,859 £52,517,187 46,237 £17,338,951 29,651 £8,474,909 2,294 
9. Primary care case identification, 
no cascade testing from new index 
cases 
£2,351,161 £4,919,686 £6,220,205 £13,491,052 0 £0 19,763 £6,220,205 0 
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Long term results 
 
After adjusting for age, the Markov modules resulted in the mean payoffs for the four cohorts (see 
Supplementary Material). These figures represented the expected total, discounted cost and health 
outcomes experienced by each cohort over their lifetimes. Differences in QALYs and costs between 
males and females were predominantly due to different baseline risks of cardiovascular events and 
different adjustments in those risks due to FH. The figures show that if a case of FH can be found, it is 
highly cost effective to treat. Indeed, it may be cost saving especially for women of all ages and 
younger men due to the large reduction in CVD event costs outweighing the cost of high intensity 
statins.  
 
Short and long term results combined 
 
Strategy 3 was the most cost-effective strategy with an incremental cost-effectiveness ratio (ICER) of 
£13,365 per QALY. Strategy 4 had an ICER of £3,254 per QALY but Strategy 3 was preferred 
because it maximised health gain up to NICE’s £20,000 per QALY threshold. However, the total 
costs and QALYs for Strategies 3 and 4 are very similar. Strategy 2 (cascade testing only) had an 
ICER of £4,740 per QALY compared with Strategy 1 (no intervention) but was extendedly dominated 
by Strategy 4 compared with Strategy 1. Strategies 5 and 6 were excluded through simple domination 
as Strategies 3 and 4 provided more health benefits at less cost. Strategies 7 and 8 had ICERs of 
£63,514 per QALY and £82,388 per QALY respectively, well above NICE’s cost effectiveness 
threshold. Strategy 9, which involved searching primary care databases for people with high 
cholesterol and prescribing all high-intensity statins without genetic testing (i.e. regardless of FH 
status) was found to be cost-effective compared with cascade testing alone (ICER £1,186/QALY); 
however, additional health benefits for an acceptable additional cost were available with Strategy 3 
(genetic testing prior to treatment). The cost-effectiveness frontier (supplementary material) shows 
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that although Strategies 9 and 4 are cost effective relative to Strategy 1, Strategy 3 is the most cost 
effective before the ICERs exceed the cost-effectiveness threshold for Strategies 7 and 8.  
 
 
Table 3: Incremental results, base case 
Strategy Cost (£) QALYs ICER 
1. No cascade testing and no case identification 6797.32 11.4079 £0 
2. Cascade testing 6843.092 11.41755 Ext.Dom 
9. Primary care case identification, no cascade testing from new index 
cases 
6851.824 11.45383 £1,186 
4. Primary care case identification, clinical assessment with DLCN 
criteria 
6882.477 11.46325 £3,254 
3. Primary care case identification, clinical assessment with SB 
criteria a 
6886.718 11.46357 £13,365 
6. Secondary care case identification, clinical assessment with DLCN 
criteria 
6982.246 11.41991 Dominated 
5. Secondary care case identification, clinical assessment with SB 
criteria 
7004.111 11.41999 Dominated 
8. Primary and secondary care case identification, clinical assessment 
with DLCN criteria 
7021.597 11.4657 £63,514 
7. Primary and secondary care case identification, clinical assessment 
with SB criteria 
7047.737 11.46601 £82,388 
QALY: Quality-adjusted life year; ICER: Incremental cost-effectiveness ratio (calculated by dividing the 
difference in costs by the difference in QALYs for each strategy compared with the next best alternative 
strategy, excluding dominated and extendedly dominated options);  
a Indicates the most cost-effective strategy because it maximises health gain up to the cost-effectiveness 
threshold, £20,000/QALY 
Strategies are listed in order of increasing mean cost to assist with the reporting and interpretation of 
incremental analysis.  
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Sensitivity analysis results 
 
The results of one-way sensitivity analyses conducted for 12 parameters were ranked by NMB (see 
Supplementary Material). When the prevalence of FH in people identified for further investigation in 
primary care was decreased to 15%, Strategy 4 became the most cost-effective strategy with Strategy 
3 ranked second. When the prevalence of FH in people with early MI was increased to an upper 
estimate of 8.3%, Strategy 8, primary care and secondary care case identification with clinical 
assessment using the DLCN criteria, became the most cost-effective strategy. The threshold at which 
Strategy 3 no longer had the maximum NMB was around 4.3% (compared with a base case of 1.3%). 
When the proportion of people in primary care databases for who data is available was increased to 
100% from the base case of 31%, Strategy 3 remained the most cost-effective option, although this 
had the expected consequence of very directly affecting the short term resource impact. The 
proportion of people already taking lipid modification pre-intervention was varied from 10% to 99% 
and made no difference to the order of preferred strategies. When the SB and DLCN criteria were 
varied to ‘definite only’ criteria it resulted in less net monetary benefits compared with the more 
inclusive criteria. When the number of relatives approached for cascade testing per index case was 
increased to the maximum of 12, Strategies 7 and 8 became the most cost effective.  Threshold 
analysis revealed that the preferred strategies change once 8 relatives are contacted per index case, 
which is 4 times the base case value. An alternative search criteria requiring people to have total 
cholesterol > 9.3 mmol/L and triglycerides < 2.3 mmol/L before clinical assessment did not change 
the ranking of strategies but did slightly decrease the total resource impact of case identification 
strategies due to a lower number of people requiring clinical assessment. When the CHD relative risk 
due to FH was arbitrarily doubled and halved, the relative cost effectiveness between strategies did 
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not change. When the risk of CHD events was matched to those observed in the SAFEHEART study 
(7.53% vs. 15-44% in the base case), the cost-effectiveness conclusions of the model remained largely 
the same. 
 
Probabilistic sensitivity analysis 
 
Probabilistic sensitivity analysis indicated that Strategy 3 had a 57% probability of being the most 
cost-effective option at a threshold of £20,000 per QALY (Table 4). Strategy 4 had a 41% probability 
of being the most cost effective option, although the confidence intervals of NMBs for these two 
strategies overlapped almost exactly.  
 
The cost-effectiveness acceptability curve shows the probability of selected strategies (2, 3, 4 and 9) 
being cost effective at different thresholds relative to other selected thresholds (Figure 2). Three 
strategies were selected for this analysis based on their deterministic results. Strategy 4 had the 
highest probability of being cost effective up to a threshold ICER of £17,000 per QALY. Strategy 3 
had the highest probability of being cost effective up between ICERs of £17,000 and £30,000 per 
QALY. 
 
Table 4: Results of probabilistic sensitivity analysis 
Strategy NMB (£) Probability 
most cost 
effective 
Mean Lower 95% 
CI 
Upper 95% 
CI 
1. No cascade testing and no case identification 222,016 207,292 234,828 0.00% 
2. Cascade testing 222,165 207,406 235,010 0.00% 
3. Primary care case identification, clinical assessment with 
SB criteria 
223,029 208,557 235,617 56.80% 
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4. Primary care case identification, clinical assessment with 
DLCN criteria 
223,027 208,539 235,617 40.70% 
5. Secondary care case identification, clinical assessment 
with SB criteria 
222,051 207,280 234,879 0.00% 
6. Secondary care case identification, clinical assessment 
with DLCN criteria 
222,072 207,302 234,913 0.00% 
7. Primary and secondary care case identification, clinical 
assessment with SB criteria 
222,915 208,478 235,464 0.10% 
8. Primary and secondary care case identification, clinical 
assessment with DLCN criteria 
222,936 208,483 235,493 2.40% 
9. Primary care case identification, no cascade testing from 
new index cases 
222,875 208,247 235,562 0.10% 
 
 
Figure 2: Cost-effectiveness acceptability curve 
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Discussion 
 
This economic analysis found that searching primary care databases for people with total cholesterol 
> 9.3 mmol/L and providing clinical assessment using the SB diagnostic criteria in addition to cascade 
testing was cost effective with an ICER of £13,365 per QALY (compared with Strategy 4) and a 57% 
probability of being cost effective. Clinical assessment using the DLCN criteria following primary 
care database searching had a 41% probability of being the most cost-effective strategy with costs and 
QALYs that were very close to the SB option (Strategy 3). The addition of primary care case finding 
to cascade testing therefore had a 95% probability of being cost-effective and absolute differences in 
costs and QALYs between the DLCN and SB criteria were small. Analysis of the total short term 
resource impact showed that primary care case identification can be implemented at a cost of £22 
million and diagnose over 7,700 people with FH. By contrast, the addition of case identification in 
secondary care would cost double this amount and is unlikely to be cost effective based on a 
prevalence of FH in people with a history of MI of 1.3%.  
  
The analysis confirmed the cost effectiveness of cascade testing compared with no cascade testing 
with an ICER of £4,470 per QALY and 100% likelihood the strategy is cost effective at a threshold of 
£20,000 per QALY, confirming the conclusions of previous economic analyses.6-9 However, 
additional health benefits are achievable at an acceptable cost by adopting case identification 
strategies in primary care in addition to cascade testing. The results were robust to one-way sensitivity 
analysis of the cost of genetic testing, realistic numbers of relatives approached for cascade testing 
and take up rates across all subgroups. Where cost-effectiveness results changed, primary care case 
identification remained cost effective and only the preferred diagnostic criteria changed. Referring 
both possible and definite cases of FH for genetic testing based on the SB criteria from primary care 
remained cost effective compared with referring only definite cases because the long term 
consequences of missed FH diagnoses outweighed the short term cost savings made available by 
referring definite cases only.  
  24 
 
The dominant role of primary care identification compared with secondary care identification was 
altered if the prevalence of FH in people with premature MI increased. If the prevalence of FH in 
people with MI was over 4%, expanding case identification to secondary care settings in addition to 
primary care settings and cascade testing may be cost effective. This parameter (1.3%) was informed 
by the only study identified in the literature at the time of analysis that investigated the prevalence of 
genetically-confirmed FH in this population, with a cohort of 231 patients.24 However, a recent study 
of 103 patients suggests that the prevalence of genetically-confirmed FH in this population could be 
as high as 8.9%.30 In the present analysis, the highest prevalence used in sensitivity analysis was 8.3% 
but this was based on clinical diagnosis, and thus overestimates the true prevalence of genetically-
confirmed FH.25 The present analysis clearly demonstrates the importance of research to identify the 
true prevalence of genetically-confirmed FH in people with a history of MI. 
 
There are a number of advantages to this analysis. To our knowledge, it is the first time case 
identification in addition to cascade testing has been compared with cascade testing alone. In addition, 
a novel meta-analysis based on a systematic review of the diagnostic accuracy of clinical assessment 
tools compared with genetic testing was used to inform the model. The lifetime impacts of treating FH 
and polygenic hypercholesterolaemia were taken into account. The calculation of total short term 
resource impact is an additional important contribution to the evidence available to decision-makers. 
The treatment effect following diagnosis of FH was based on the reduction of the risk of CHD events 
only. This was a conservative approach as additional reduction in non-CHD mortality are likely due to 
lifestyle changes motivated by a person’s knowledge of their FH status.3 The NICE Guideline 
Committee viewed the number of relatives invited for cascade testing as quite conservative as it was 
based on an incomplete national cascade testing service. Families are geographically spread and, if 
most of the relatives for any given index case are in an area that does not have a FH service, then the 
yield from the index case is minimal. In the committee’s view it is possible to achieve a higher yield 
from cascade testing if it is provided across England.  
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Interpretation of these results needs to take into consideration that cost effectiveness of the primary 
care case identification strategies in this model was influenced by the number of people with 
polygenic hypercholesterolaemia that come into contact with primary care as a result of the 
interventions. Although the guideline update focused on familial hypercholesterolaemia, the NICE 
Guideline Committee took the view that the polygenic index cases would be impacted by the 
interventions and should continue to be included in the model. 
 
This analysis has a number of limitations, mainly related to the assumptions required to operationalise 
the model. Genetic testing was assumed to have perfect sensitivity and specificity. This was a 
limitation common to all strategies so was thought not to affect overall conclusions, however, it 
marginally favoured the SB criteria due to undervaluing the costs of its lower specificity. A single 
probability of take up was used to represent take up across the entire care pathway. Factoring in 
differential take up rates may either increase or decrease the relative cost effectiveness of 
interventions depending on setting and where they occur in the care pathway. Adherence to lipid 
modification treatment was assumed to be 100%. This may have overestimated the cost effectiveness 
of all interventions compared with no intervention, although given that ranking of the strategies was 
completely insensitive to the number of people already taking statins within the model, this limitation 
was assessed as minor. The minimum starting age was 40 as this was the lowest age adopted in 
NICE’s lipid modification model and aligns with the NHS vascular check programme. This limitation 
likely led to an underestimation of the cost effectiveness of all strategies due to the increased risk of 
CHD at younger ages due to FH. There was uncertainty as to the true relative risk of CHD and 
relative treatment effect between people with and without FH among those with a total cholesterol of 
>9.3 mmol/L, however, various theoretical data were tested in sensitivity analysis but this did not 
affect conclusions. There were also no data to inform the distribution of risk scores in the target 
population but the rankings were insensitive to extreme high and low values so this limitation was 
considered minor. Further, overlap of strategies was not accounted for. It is likely that an intervention 
of primary care case identification will identify people that have already been diagnosed with FH 
through cascade testing, and vice versa. However, no data were identified in the literature to inform 
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the inclusion of this into the model. Finally, the take up of clinical assessment by people identified by 
a primary care database search was informed by an Australian study and may not be generalizable to 
other populations.14  
 
It is possible that more accurate database search criteria exist in the literature.31  However, they could 
not be used to inform this model due to diagnosis of FH being based on clinical assessment rather 
than genetic testing, leaving the true prevalence of FH within these populations uncertain. Further 
research in this area has the potential to ensure primary care resources are focussed on those people 
most likely to have FH by establishing the accuracy of database search algorithms based on 
genetically-confirmed diagnoses. Further research into the most effective case-finding methods would 
be of high value. This research could also be used to clarify which clinical assessment tool is the most 
appropriate for use in primary care.   
 
Another area that should be prioritised for further research is the prevalence of FH in people with a 
history of MI. This analysis has shown the cost effectiveness of secondary care case identification 
strategies is contingent on this figure. The short term resource impact of secondary care case 
identification was estimated to be at least £30 million and has the potential to diagnose thousands of 
people with FH, but cannot be currently regarded as cost effective due to the inconsistent nature of the 
evidence.  
 
 
Conclusion 
 
The identification of FH by analysing primary care databases in addition to cascade testing is likely to 
be a cost effective strategy. The SB criteria is likely to be more cost effective than the DLCN criteria 
although the results for both are similar. Strategies that involve case identification in people with early 
MI are unlikely to be cost effective given the current state of evidence on the prevalence of FH in 
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people with a history of MI. This cost-effectiveness analysis provides sufficient evidence to suggest 
GPs develop a formalised method to assess for FH using one of the diagnostic criteria with a low 
threshold for referral, specifically both possible or definite when using the SB criteria, or scores >5 
when using the DLCN criteria. These results are generalisable to similar health care systems in other 
countries, provided routine patient data is collected and able to be searched by GP surgeries, genetic 
testing for FH is readily available, and the cost of these services are comparable. Due to the 
combination of high benefits and low ICER, if GPs in other health care systems are able to directly 
order genetic tests without referral to specialist care, searching electronic health records for people 
with FH will almost certainly be cost-effective.  
 
 
 
 
 
 
 
 
Financial support 
SEH was a British Heart Foundation (BHF) Professor funded by a BHF grant (BHF PG08/008) and 
by the NIHR UCLH BRC. This work was conducted at the National Institute of Health and Care 
Excellence (NICE). RM, SB and HM are employees of NICE. PC was an employee of NICE at the 
time this work was conducted.  
 
Acknowledgements 
The authors would like to acknowledge the advice, time and commitment provided by the committee 
members of the NICE Guideline Committee and members of the Technical Team at NICE.  
  28 
References 
 
1. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is 
underdiagnosed and undertreated in the general population: guidance for clinicians to prevent 
coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 
2013; 34(45): 3478-90a. 
2. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial 
hypercholesterolaemia: a long term cohort study. BMJ 2008; 337: a2423. 
3. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in 
statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry 
study. Eur Heart J 2008; 29(21): 2625-33. 
4. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Mutations causative of familial 
hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population 
Study estimated a prevalence of 1 in 217. Eur Heart J 2016; 37(17): 1384-94. 
5. Pedersen K, Besford J. National Clinical Audit of the Management of Familial 
Hypercholesterolaemia 2010. Clinical Standards Dept RCP London 2011. 
6. Nherera L, Marks D, Minhas R, Thorogood M, Humphries SE. Probabilistic cost-effectiveness 
analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and 
identification strategies. Heart 2011; 97(14): 1175-81. 
7. Ademi Z, Watts GF, Pang J, et al. Cascade screening based on genetic testing is cost-effective: 
evidence for the implementation of models of care for familial hypercholesterolemia. Journal of 
clinical lipidology 2014; 8(4): 390-400. 
8. National Collaborating Centre for Primary Care. Clinical Guideline 71: Familial 
Hypercholesterolaemia. London, United Kingdom; 2008. 
9. Kerr M, Pears R, Miedzybrodzka Z, et al. Cost effectiveness of cascade testing for familial 
hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK. Eur 
Heart J 2017. 
10. Qureshi N, Weng S, Tranter J, El-Kadiki A, Kai J. Feasibility of improving identification of 
familial hypercholesterolaemia in general practice: intervention development study. BMJ Open 
2016; 6(5): e011734. 
11. Bell DA, Kirke AB, Barbour R, et al. Can patients be accurately assessed for familial 
hypercholesterolaemia in primary care? Heart, Lung and Circulation 2014; 23(12): 1153-7. 
12. Gray J, Jaiyeola A, Whiting M, Modell M, Wierzbicki A. Identifying patients with familial 
hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre. 
Heart 2008; 94(6): 754-8. 
13. Green P, Neely D, Humphries SE, Medway FHASC. Improving detection of familial 
hypercholesterolaemia in primary care using electronic audit and nurse-led clinics. J Eval Clin Pract 
2016; 22(3): 341-8. 
14. Kirke AB, Barbour RA, Burrows S, et al. Systematic detection of familial 
hypercholesterolaemia in primary health care: a community based prospective study of three 
methods. Heart, Lung and Circulation 2015; 24(3): 250-6. 
15. Norsworthy PJ, Vandrovcova J, Thomas ER, et al. Targeted genetic testing for familial 
hypercholesterolaemia using next generation sequencing: a population-based study. BMC medical 
genetics 2014; 15(1): 70. 
16. Troeung L, Arnold-Reed D, Chan She Ping-Delfos W, et al. A new electronic screening tool for 
identifying risk of familial hypercholesterolaemia in general practice. Heart 2016; 102(11): 855-61. 
17. National Institute for Health and Care Excellence. Addendum to Clinical Guideline CG71, 
Familial hypercholesterolaemia. London, UK; 2017. 
  29 
18. Sharifi M, Futema M, Nair D, Humphries SE. Genetic Architecture of Familial 
Hypercholesterolaemia. Curr Cardiol Rep 2017; 19(5): 44. 
19. Talmud PJ, Futema M, Humphries SE. The genetic architecture of the familial 
hyperlipidaemia syndromes: rare mutations and common variants in multiple genes. Curr Opin 
Lipidol 2014; 25(4): 274-81. 
20. Khera AV, Won HH, Peloso GM, et al. Diagnostic Yield and Clinical Utility of Sequencing 
Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll 
Cardiol 2016; 67(22): 2578-89. 
21. Sharifi M, Higginson E, Bos S, et al. Greater preclinical atherosclerosis in treated monogenic 
familial hypercholesterolemia vs. polygenic hypercholesterolemia. Atherosclerosis 2017; 263: 405-
11. 
22. Haralambos K, Ashfield-Watt P, McDowell IF. Diagnostic scoring for familial 
hypercholesterolaemia in practice. Curr Opin Lipidol 2016; 27(4): 367-74. 
23. Futema M, Kumari M, Boustred C, Kivimaki M, Humphries SE. Would raising the total 
cholesterol diagnostic cut-off from 7.5 mmol/L to 9.3 mmol/L improve detection rate of patients 
with monogenic familial hypercholesterolaemia? Atherosclerosis 2015; 239(2): 295-8. 
24. Wald DS, Bangash FA, Bestwick JP. Prevalence of DNA-confirmed familial 
hypercholesterolaemia in young patients with myocardial infarction. European journal of internal 
medicine 2015; 26(2): 127-30. 
25. De Backer G, Besseling J, Chapman J, et al. Prevalence and management of familial 
hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European 
Society of Cardiology. Atherosclerosis 2015; 241(1): 169-75. 
26. Bhatnagar P, Wickramasinghe K, Williams J, Rayner M, Townsend N. The epidemiology of 
cardiovascular disease in the UK 2014. Heart 2015; 101(15): 1182-9. 
27. Hadfield SG, Horara S, Starr BJ, et al. Family tracing to identify patients with familial 
hypercholesterolaemia: the second audit of the Department of Health Familial 
Hypercholesterolaemia Cascade Testing Project. Ann Clin Biochem 2009; 46(Pt 1): 24-32. 
28. Perez de Isla L, Alonso R, Mata N, et al. Predicting Cardiovascular Events in Familial 
Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort 
Study). Circulation 2017; 135(22): 2133-44. 
29. Curtis L, Burns A. Unit Costs of Health and Social Care 2016. Canterbury: The University of 
Kent, 2016. 
30. Amor-Salamanca A, Castillo S, Gonzalez-Vioque E, et al. Genetically Confirmed Familial 
Hypercholesterolemia in Patients With Acute Coronary Syndrome. J Am Coll Cardiol 2017; 70(14): 
1732-40. 
31. Weng SF, Kai J, Andrew Neil H, Humphries SE, Qureshi N. Improving identification of familial 
hypercholesterolaemia in primary care: derivation and validation of the familial 
hypercholesterolaemia case ascertainment tool (FAMCAT). Atherosclerosis 2015; 238(2): 336-43. 
 
 
